EMTN Programme: Publication of Final Terms

Source: RNS
RNS Number : 2638T
Reckitt Benckiser Group PLC
20 June 2024
 

20 June 2024

 

RECKITT BENCKISER GROUP PLC

 

EMTN Programme: Publication of Final Terms

 

Reckitt Benckiser Group plc (the "Company"), together with Reckitt Benckiser Treasury Services plc (the "Issuer"), announce that on 13 June 2024, they successfully launched and priced the following notes under the GBP 10,000,000,000 Euro Medium Term Note Programme of the Issuer and Reckitt Benckiser Treasury Services (Nederland) B.V.:

 

-     EUR 900,000,000 3.625% Fixed Rate Senior Notes due 20 June 2029; and

-     GBP 300,000,000 5.000% Fixed Rate Senior Notes due 20 December 2032,

 

(together the "Notes"), each issued by the Issuer and guaranteed by the Company. The Notes are expected to be issued on 20 June 2024.

 

The Final Terms dated 18 June 2024 relating to the Notes are available for viewing. To view the full documents, please paste the following URL into the address bar of the browser:

 

https://reckitt.com/investors/your-shareholding/emtn-programme-documents/

 

A copy of the Final Terms has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

The Final Terms should be read and construed in conjunction with the Base Prospectus dated 3 June 2024.

 

For further Information:

 

Richard Joyce                                                             +44 (0)7807 418516

Investor Relations

 

Catheryn O'Rourke                                                   +44 (0) 1753 217 800

Company Secretary

 

About Reckitt:  

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest‐quality hygiene, wellness and nourishment is a right, not a privilege.

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Biofreeze, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

Every day, more than 30 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose‐ led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com.

* Reckitt is the trading name of the Reckitt Benckiser group of companies 

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

 

This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire any securities.

 

The securities referred to herein and the guarantee thereof have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and are subject to Unites States tax law requirements. Subject to certain exceptions, the securities referred to herein may not be offered, sold or delivered in the United States (as defined in Regulation S under the Securities Act) or to, or for the account or benefit of, U.S. persons (as defined in the U.S. Internal Revenue Code of 1986, as amended, and regulations thereunder). The Base Prospectus may not be accessed from, or transmitted in or into, the United States. Accordingly, these securities may not be offered, sold or delivered in the United States.

 

Please note that the information contained in the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Final Terms and the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

 

Your right to access this service is conditional upon complying with the above requirements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTSEDFESELSEEM